The Latest Breaking News from CORT

A detailed rundown of the hottest guitar gear to hit the market over the past year. Here, we dive into the standout pieces.

Philipsen takes second victory of the race ahead of Van Aert and Pascal Ackermann

If keeping up with a tidy, clean living room is keeping you up at night, make these simple switches that will make it easier to reset every day

New five-string model pairs own-brand headless tech with refined sculpting for a compact and tonally balanced build

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

The brand is continuing its tradition of offering well-spec'd builds at affordable price points with a stealthy 7-string that comes loaded with Seymour Duncan Sentient and Nazgûl pickups

It's right up there in the extended-range stakes… but not much of a change from the previous model

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear promising. Thus, investors could consider buying biotech stocks Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Incyte (INCY), and Exelixis (EXEL) for substantial gains. Read on….

Following the Duality and Mutility, this new offering looks to stretch beyond metal and rock realms and cater directly to the gigging guitarist demanding a do-it-all workhorse